ERBB2 and ovarian carcinoma: To determine if HER2 antigen expression levels impact NK cell activation via the TriKE, a limiting dose of CAM1615HER2 (0.3 nM) was added to the assay and tested against a high density HER2 ovarian cancer cell (SKOV-3) versus low-density lines (OVCAR3 and OVCAR5).